A phase II trial of amonafide in patients mixed mesodermal tumors of the uterus: A gynecologic oncology group study

Robert Asbury, John A. Blessing, Edward Podczaski, Harrison Ball

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Amonafide demonstrated a poor response rate and substantial toxicity in patients who had measurable, advanced mixed mesodermal tumors of the uterus. Amonafide-a drug that acts through intercalation of tumor DNA-was used to treat 16 patients who had measurable, advanced mixed mesodermal tumors of the uterus as part of a Gynecologic Oncology Group (GOG) Phase II study. The starting dose was 300 mg/m2 intravenously over 1 hour for 5 consecutive days every 3 weeks. Severe or life-threatening hematologic toxicity occurred in 50% of the patients. Two patients experienced vomiting requiring hospitalization. Other toxicities were not severe. One patient had a partial response and one had stable disease, each lasting 4 months. This dose schedule was associated with poor response rate and substantial toxicity.

Original languageEnglish (US)
Pages (from-to)306-307
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume21
Issue number3
DOIs
StatePublished - Jun 1998

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this